Basilea Pharmaceutica AG is a biopharmaceutical company based in Basel, Switzerland, dedicated to developing innovative treatments for oncology and anti-infective diseases. It markets isavuconazole, an azole antifungal medication used to treat invasive aspergillosis and mucormycosis under the brand name Cresemba, available in the United States, the European Union, and other international markets. The company also offers ceftobiprole, an intravenous antibiotic effective against community and hospital-acquired pneumonia, and is conducting Phase III trials for its use in treating acute bacterial skin and skin structure infections, as well as Staphylococcus aureus bacteremia, branded as Zevtera. Additionally, Basilea is advancing several pipeline candidates, including Derazantinib for intrahepatic cholangiocarcinoma, BAL101553 as a tumor checkpoint controller, and BAL3833, a small-molecule drug targeting panRAF/SRC kinases. Founded in 2000, Basilea aims to address significant medical challenges posed by rising resistance to current therapies.
uMotif Limited is a healthcare technology company that develops a data capture solution designed for clinical research. Founded in 2012 and based in London, uMotif operates a patient-centered platform that facilitates the collection and validation of various forms of patient-generated data, including electronic consent, electronic clinical outcome assessments, and patient-reported outcomes. This platform enables researchers and clinicians to gather comprehensive health data that is essential for medical research, benefiting pharmaceutical companies, medical device manufacturers, biotech firms, contract research organizations, and academic institutions. By enhancing the data collection process, uMotif supports the advancement of clinical research across diverse health conditions.
Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.
Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.
Osmotica Pharmaceutical is a specialty pharmaceutical company focused on developing and commercializing both branded and generic products, primarily in the United States, Argentina, and Hungary. The company’s product portfolio includes treatments for movement disorders such as multiple sclerosis and Parkinson's disease, along with various central nervous system and neurology-based therapies. Key products include M-72, an extended-release tablet for ADHD; Osmolex ER, used for Parkinson’s and drug-induced reactions; and Arbaclofen, currently in phase III trials for multiple sclerosis spasticity. Osmotica also offers women's health products like Divigel for menopause and OB Complete, a dietary supplement for pregnancy. Additionally, its pipeline features a range of medications for conditions such as depression, pain, hypertension, and overactive bladder. Founded in 1986 and headquartered in Bridgewater, New Jersey, Osmotica has manufacturing facilities in the United States and Spain. The company was previously known as Osmotica USA Corp. and operates as a subsidiary of Vertical / Trigen Holdings LLC.
Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.
BioCryst Pharmaceuticals, Inc. is a biotechnology company that specializes in the discovery and development of oral, small-molecule medicines for rare diseases with significant unmet medical needs. The company’s approved products include RAPIVAB, an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, and ORLADEYO, an oral medication for preventing hereditary angioedema attacks in patients aged 12 and older. BioCryst is advancing several candidates in clinical trials, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, aimed at treating RNA viruses such as Ebola and Zika. The company engages in collaborations with various institutions, including government health agencies and pharmaceutical partners, to enhance its research and development efforts. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst Pharmaceuticals continues to focus on innovative therapies that address critical health challenges.
Private Equity Round in 2019
ArisGlobal LLC specializes in cloud-based software solutions for the life sciences industry, providing a comprehensive platform known as LifeSphere. This platform facilitates the research and development processes for over 250 life sciences companies, contract research organizations, and government health authorities globally. ArisGlobal's offerings include pharmacovigilance and safety solutions, regulatory affairs management, clinical operations support, and medical information management. The company employs advanced cognitive computing and machine learning to enhance the automation of critical functions such as drug safety, regulatory compliance, and medical affairs. Founded in 1987 and headquartered in Stamford, Connecticut, ArisGlobal has established regional offices in various locations, including Europe, India, Japan, and China. Its solutions aim to streamline collaboration among cross-functional teams and accelerate the development of safer products while ensuring compliance with regulatory requirements.
Secura Bio is an integrated biopharmaceutical company based in Las Vegas, Nevada, with additional operations in San Diego. Founded in 2019, the company focuses on developing and commercializing innovative therapies, particularly in the oncology sector. Secura Bio aims to provide patients with access to significant treatment options that can address serious illnesses. By prioritizing the needs of patients and physicians, the company strives to deliver life-changing products that enhance the diagnosis and treatment of critical health conditions.
Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief. It was founded in 2007 and headquartered in Malvern, Pennsylvania.
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities.
It was founded in 2010 and headquartered in Menlo Park, California.
Private Equity Round in 2018
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Private Equity Round in 2018
Sound Physicians is a provider of inpatient physician services focused on enhancing the quality and satisfaction of healthcare for its hospital partners. Founded and managed by physicians, the company employs over 1,000 hospitalist and post-acute care physicians who deliver care in more than 70 hospitals and a growing number of post-acute care centers across the United States. Sound Physicians offers a comprehensive range of services, including emergency medicine, critical care, hospital medicine, population health, telemedicine, and physician advisory services. By partnering closely with healthcare providers, the company aims to improve both clinical outcomes and financial performance within healthcare systems.
Veloxis Pharmaceuticals A/S is a specialty pharmaceutical company dedicated to improving the lives of transplant patients through the development and commercialization of targeted medications. The company focuses on Envarsus XR, a once-daily tacrolimus tablet designed to prevent organ rejection in kidney transplant recipients. Envarsus XR has demonstrated non-inferiority to the market-leading immunosuppressant, Prograf, in key clinical trials. Veloxis employs its proprietary MeltDose technology to enhance the absorption and bioavailability of orally administered drugs, which has been validated through clinical studies and is also used in the formulation of Envarsus. Founded in 2002 as a spin-off from H. Lundbeck A/S, Veloxis is headquartered in Copenhagen, Denmark, and operates a subsidiary in the United States. The company has received regulatory approvals for Envarsus XR in both the European Union and the United States, underscoring its commitment to addressing the needs of transplant patients.
Private Equity Round in 2018
VillageMD is a healthcare management service provider that partners with primary care physicians to enhance clinical outcomes in a rapidly evolving healthcare environment. Founded in 2013 and headquartered in Chicago, Illinois, the company offers a comprehensive suite of tools and services, including technology, operations, staffing support, clinical innovation, and analytics. VillageMD aims to help physicians and healthcare organizations transition to a primary care-led, value-based care model. It collaborates with physician groups, independent practice associations, and health systems to improve patient care quality, optimize the patient experience, and reduce costs. The company serves various markets across the United States, including cities like Chicago, Houston, and Indianapolis, positioning itself as a leader in developing a high-performing primary care network.
OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal "Bi-Directional Delivery" which allows drugs to be more efficiently delivered to the nasal cavity. By applying its drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices. The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a faster onset of action, greater effect with a lower dose, and reduced side effects. The company has offices in Norway and the UK.
Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief. It was founded in 2007 and headquartered in Malvern, Pennsylvania.
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
Pharmaceutics International, Inc. is a contract development and manufacturing organization that specializes in dosage form development and cGMP manufacturing services for the biotech and specialty pharmaceutical sectors. Founded in 1994 and headquartered in Hunt Valley, Maryland, the company offers a diverse range of dosage forms, including conventional and controlled-release tablets and capsules, soft gels, liquid formulations, inhalation products, sterile injectables, and more. In addition to manufacturing, Pharmaceutics International provides services such as pre-formulation, clinical trial materials production, commercial manufacturing, and clinical packaging and labeling. The company is committed to delivering high-quality services and has built a balanced client base that includes major multinational and emerging pharmaceutical companies worldwide. Its focus on scientific expertise, customer service, and quality has positioned Pharmaceutics International as a key player in pharmaceutical product development outsourcing.
Medicrea International SA specializes in the design, manufacture, and distribution of spinal implants, operating both in France and internationally. Established in 1990 and headquartered in Rillieux-la-Pape, France, the company offers a comprehensive range of products, including various systems for thoraco-lumbar fixation, cervical interbody devices, and specialized implants for treating conditions such as scoliosis, degenerative diseases, and trauma. Notable product lines include the PASS series, which encompasses polyaxial and posterior fixation systems, as well as the IMPIX series, featuring sterile PEEK Optima cervical and lumbar interbody devices. Medicrea focuses on delivering innovative technologies aimed at improving patient outcomes and supporting healthcare professionals in surgical procedures. The company has been dedicated to advancing spinal care, leveraging over 18 years of experience in the field. As of late 2020, Medicrea operates as a subsidiary of Covidien Group S.a.r.l.
Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.
Halozyme Therapeutics is a biotechnology company that develops and commercializes innovative therapies, particularly in oncology and drug delivery. The company utilizes its proprietary ENHANZE technology, which is based on a recombinant human hyaluronidase enzyme, to facilitate subcutaneous delivery of biologics, improving the absorption and dispersion of injectable therapeutics. Its product portfolio includes Hylenex, designed for fluid administration and enhancing drug absorption, along with various development candidates targeting significant medical needs in cancer and immunodeficiency disorders. Notable therapies being developed include those for breast cancer, non-Hodgkin lymphoma, multiple sclerosis, and other conditions. Halozyme has established collaborations with major pharmaceutical companies, leveraging its technology to enhance therapeutic efficacy. Founded in 1998 and headquartered in San Diego, California, the company aims to address unmet medical needs through its innovative therapeutic approaches and partnerships.
Clover Health is a health insurance company that specializes in providing Medicare Advantage plans for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company also has offices in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health operates a Preferred Provider Organization (PPO) platform that aims to enhance the quality of life for its members through patient-centered analytics and dedicated care management. By utilizing advanced analytics and custom software, Clover Health directs its clinical staff to proactively address gaps in care, focusing on preventive measures and chronic disease management. Its approach not only aims to improve health outcomes but also seeks to reduce unnecessary healthcare spending. The company primarily generates revenue through its insurance segment, which offers both PPO and Health Maintenance Organization (HMO) plans.
Clover Health is a health insurance company that specializes in providing Medicare Advantage plans for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company also has offices in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health operates a Preferred Provider Organization (PPO) platform that aims to enhance the quality of life for its members through patient-centered analytics and dedicated care management. By utilizing advanced analytics and custom software, Clover Health directs its clinical staff to proactively address gaps in care, focusing on preventive measures and chronic disease management. Its approach not only aims to improve health outcomes but also seeks to reduce unnecessary healthcare spending. The company primarily generates revenue through its insurance segment, which offers both PPO and Health Maintenance Organization (HMO) plans.
Apollo Endosurgery is a medical technology company specializing in the design, development, and commercialization of devices aimed at enhancing gastrointestinal therapeutic endoscopy. Founded in 2005 and headquartered in Austin, Texas, the company offers a range of products, including the OverStitch Endoscopic Suturing System and the Orbera intragastric balloon system. These devices enable physicians to perform advanced endoscopic procedures, such as placing full-thickness sutures and reducing stomach capacity to aid in weight loss. Additionally, Apollo provides aftercare support through the Orbera Coach program. The company's products are utilized by gastroenterologists and bariatric surgeons across the United States, Brazil, Australia, and various European countries, addressing conditions like gastrointestinal perforations, chronic fistulas, and abnormal lesions. Apollo Endosurgery's innovations are rooted in collaboration with a network of leading gastroenterologists and surgeons who have sought to advance the field of therapeutic flexible endoscopy since 1998.
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Retrophin is a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin’s lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for FSGS during 2013.
Retrophin is a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin’s lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for FSGS during 2013.
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products primarily for the pediatric market. The Company’s pediatric products, designed to improve the health and well-being of children, are focused in the specific areas of allergy, upper respiratory, including nasal, chest congestion and cough, antibiotics and dermatology, including head lice, and contact dermatitis. The Company promotes its products through a sales and marketing organization with approximately 55 sales representatives, primarily in highly populated states, targeting pediatric and high-prescribing physicians that are in the top decile of physicians that prescribe its products. The Company’s current operating plan focuses on maximizing sales of its existing product portfolio. In addition, Pernix plans to accelerate growth by launching new products, line extensions, and new formulations and by acquiring and licensing approved products.
SynCardia Systems, Inc. is a medical technology company based in Tucson, Arizona, established in 2001. The company specializes in the development, manufacturing, and commercialization of the SynCardia temporary Total Artificial Heart (TAH-t). This implantable device is designed to take over the full function of a failing heart in patients experiencing advanced heart failure. The SynCardia TAH-t serves as a critical bridge to transplantation, providing patients with a means to survive until a suitable donor heart becomes available. SynCardia operates in the United States, European Union, and Canada, focusing on improving outcomes for individuals with severe heart conditions.
InnoPharma, LLC. Founded in 2005, is a privately held pharmaceutical research and development (R&D) company, based in Piscataway, New Jersey.
TRIA Beauty, Inc. specializes in the development and marketing of light-based medical devices designed for consumer use in skincare and beauty treatments. The company offers a range of products, including a hand-held diode laser for hair removal, a blue light device targeting acne-causing bacteria, a fractional non-ablative laser for skin rejuvenation, and an eye wrinkle correcting laser. These devices provide effective solutions that allow users to achieve professional results at home. TRIA Beauty's products are available through its e-commerce platform and various retail channels, including television and physical stores, across multiple regions, including the United States, Japan, and several European countries. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty was previously known as SpectraGenics, Inc. before rebranding in 2008.
Private Equity Round in 2013
TRIA Beauty, Inc. specializes in the development and marketing of light-based medical devices designed for consumer use in skincare and beauty treatments. The company offers a range of products, including a hand-held diode laser for hair removal, a blue light device targeting acne-causing bacteria, a fractional non-ablative laser for skin rejuvenation, and an eye wrinkle correcting laser. These devices provide effective solutions that allow users to achieve professional results at home. TRIA Beauty's products are available through its e-commerce platform and various retail channels, including television and physical stores, across multiple regions, including the United States, Japan, and several European countries. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty was previously known as SpectraGenics, Inc. before rebranding in 2008.
BioFire Diagnostics is a clinical diagnostics company based in Salt Lake City, Utah, that focuses on detecting pathogens and mutations for molecular diagnostics. Founded in 1990, the company holds over 70 patents related to polymerase chain reaction (PCR) technology, including innovations in rapid PCR cycling. BioFire offers nearly 200 products tailored for clinical, research, and military applications. Its services are designed to provide accurate results in syndromic infectious disease diagnostics, utilizing real-time thermocycling and mutation scanning. BioFire's diagnostic panels test for a wide range of viruses, bacteria, and antimicrobial resistance genes, thereby enabling healthcare providers to assess and improve treatment outcomes for patients of all ages.
SynCardia Systems, Inc. is a medical technology company based in Tucson, Arizona, established in 2001. The company specializes in the development, manufacturing, and commercialization of the SynCardia temporary Total Artificial Heart (TAH-t). This implantable device is designed to take over the full function of a failing heart in patients experiencing advanced heart failure. The SynCardia TAH-t serves as a critical bridge to transplantation, providing patients with a means to survive until a suitable donor heart becomes available. SynCardia operates in the United States, European Union, and Canada, focusing on improving outcomes for individuals with severe heart conditions.
Verenium possesses integrated, end-to-end capabilities in pre-treatment, novel enzyme development, fermentation, engineering, and project development and is moving rapidly to commercialize its proprietary technology for the production of cellulosic ethanol from a wide array of feedstocks, including sugarcane bagasse, dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for advanced biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.
BioFire Diagnostics is a clinical diagnostics company based in Salt Lake City, Utah, that focuses on detecting pathogens and mutations for molecular diagnostics. Founded in 1990, the company holds over 70 patents related to polymerase chain reaction (PCR) technology, including innovations in rapid PCR cycling. BioFire offers nearly 200 products tailored for clinical, research, and military applications. Its services are designed to provide accurate results in syndromic infectious disease diagnostics, utilizing real-time thermocycling and mutation scanning. BioFire's diagnostic panels test for a wide range of viruses, bacteria, and antimicrobial resistance genes, thereby enabling healthcare providers to assess and improve treatment outcomes for patients of all ages.